+

WO2008123625A1 - 補助因子による受容体の活性化方法並びにリガンド活性の利用方法 - Google Patents

補助因子による受容体の活性化方法並びにリガンド活性の利用方法 Download PDF

Info

Publication number
WO2008123625A1
WO2008123625A1 PCT/JP2008/056906 JP2008056906W WO2008123625A1 WO 2008123625 A1 WO2008123625 A1 WO 2008123625A1 JP 2008056906 W JP2008056906 W JP 2008056906W WO 2008123625 A1 WO2008123625 A1 WO 2008123625A1
Authority
WO
WIPO (PCT)
Prior art keywords
betaklotho
activity
substance
pharmaceutical composition
cofactor
Prior art date
Application number
PCT/JP2008/056906
Other languages
English (en)
French (fr)
Inventor
Masashi Suzuki
Toru Imamura
Yuriko Uehara
Kaori Motomura
Junko Oki
Syuichi Oka
Masahiro Asada
Akiko Kuramochi
Miho Kimura
Original Assignee
National Institute Of Advanced Industrial Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Advanced Industrial Science And Technology filed Critical National Institute Of Advanced Industrial Science And Technology
Priority to US12/594,210 priority Critical patent/US8697369B2/en
Publication of WO2008123625A1 publication Critical patent/WO2008123625A1/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)

Abstract

　betaKlotho又は、betaKlotho活性を増強又は阻害する物質を、FGF受容体を介したFGF21活性の調節剤として用い、これらを有効成分とする医薬組成物、特に抗メタボリックシンドローム用の医薬組成物、特に血糖値調節に関わる治療又は予防用医薬組成物を提供した。また、FGF受容体及び／又はbetaKlothoを細胞表面に発現させた細胞系を用いることによる、betaKlotho活性の昂進又は抑制する物質、FGF21様活性物質、及びbetaKlotho様活性物質それぞれのスクリーニングの系を提供した。
PCT/JP2008/056906 2007-04-06 2008-04-07 補助因子による受容体の活性化方法並びにリガンド活性の利用方法 WO2008123625A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/594,210 US8697369B2 (en) 2007-04-06 2008-04-07 Method for screening a test substance for activating a receptor associated with FGF 21 activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007-100865 2007-04-06
JP2007100865 2007-04-06
JP2007182848 2007-07-12
JP2007-182848 2007-07-12
JP2007-218588 2007-08-24
JP2007218588 2007-08-24

Publications (1)

Publication Number Publication Date
WO2008123625A1 true WO2008123625A1 (ja) 2008-10-16

Family

ID=39831075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056906 WO2008123625A1 (ja) 2007-04-06 2008-04-07 補助因子による受容体の活性化方法並びにリガンド活性の利用方法

Country Status (3)

Country Link
US (1) US8697369B2 (ja)
JP (2) JP5187837B2 (ja)
WO (1) WO2008123625A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120098871A (ko) * 2009-12-07 2012-09-05 암젠 인크 β-ＫＬＯＴＨＯ, ＦＧＦ 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
US9493530B2 (en) 2009-05-05 2016-11-15 Amgen Inc. FGF21 mutants comprising a mutation at position 98, 171 and/or 180
US10093735B2 (en) 2014-01-24 2018-10-09 Ngm Biopharmaceuticals, Inc. Beta-klotho binding proteins
EP3670534A2 (en) * 2010-04-15 2020-06-24 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
US11072640B2 (en) 2008-06-04 2021-07-27 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US11802152B2 (en) 2015-08-03 2023-10-31 Novartis Ag Methods of treating FGF21-associated disorders

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
WO2011010706A1 (ja) * 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21シスエレメント結合物質
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
CA2795281A1 (en) * 2010-04-09 2011-10-13 Curna, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
JP5927782B2 (ja) * 2010-06-15 2016-06-01 国立大学法人広島大学 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途
JP2014513981A (ja) * 2011-05-10 2014-06-19 アムジエン・インコーポレーテツド ＦＧＦＲ１とβ−ＫＬＯＴＨＯの相互作用を特異的に調節する化合物の同定方法
HUE033584T2 (hu) * 2011-05-16 2017-12-28 Hoffmann La Roche FGFR1 agonisták és alkalmazási eljárások
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
US9657075B2 (en) * 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) * 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
MX2016005101A (es) 2013-10-21 2017-01-09 Salk Inst For Biological Studi Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
US20240076332A1 (en) * 2016-10-04 2024-03-07 Svar Life Science Ab FGF21 Responsive Reporter Gene Cell Line
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FUKUMOTO S. ET AL.: "FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23", BONE, vol. 40, no. 5, 4 January 2007 (2007-01-04), pages 1190 - 1195, XP022025418, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/journal/87563282> *
GOETZ R. ET AL.: "Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members", MOLECULAR AND CELLULAR BIOLOGY, vol. 27, no. 9, 5 March 2007 (2007-03-05), pages 3417 - 3428, XP002596984, Retrieved from the Internet <URL:http://www.mcb.asm.org/cgi/reprint/MCB.02249-06v1> *
ITO S. ET AL.: "Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein", MECHANISMS OF DEVELOPMENT, vol. 98, no. 1-2, 2000, pages 115 - 119, XP027424196, DOI: doi:10.1016/S0925-4773(00)00439-1 *
KUROSU H. ET AL.: "Regulation of fibroblast growth factor-23 signaling by klotho", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 10, 2006, pages 6120 - 6123, XP002523386, DOI: doi:10.1074/JBC.C500457200 *
MOYERS J.S. ET AL.: "Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 210, no. 1, 2007, pages 1 - 6, XP009127266, DOI: doi:10.1002/jcp.20847 *
OGAWA Y. ET AL.: "BetaKlotho is required for metabolic activity of fibroblast growth factor 21", PROC. NATL. ACAD. SCI. USA, vol. 104, no. 18, 1 May 2007 (2007-05-01), pages 7432 - 7437, XP055000869, DOI: doi:10.1073/pnas.0701600104 *
URAKAWA I. ET AL.: "Klotho converts canonical FGF receptor into a specific receptor for FGF23", NATURE, vol. 444, no. 7120, 2006, pages 770 - 774 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840558B2 (en) 2008-06-04 2023-12-12 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US11072640B2 (en) 2008-06-04 2021-07-27 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
US9493530B2 (en) 2009-05-05 2016-11-15 Amgen Inc. FGF21 mutants comprising a mutation at position 98, 171 and/or 180
US8835385B2 (en) 2009-05-05 2014-09-16 Amgen Inc. FGF21 polypeptides comprising two or more mutations and uses thereof
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
EP3202787A1 (en) * 2009-12-07 2017-08-09 Amgen, Inc Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
US9493577B2 (en) 2009-12-07 2016-11-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
EP2711375A1 (en) * 2009-12-07 2014-03-26 Amgen Inc. Human Antigen Binding Proteins that bind Beta-Klotho, FGF Receptors and complexes thereof
EP2510009B1 (en) * 2009-12-07 2017-04-26 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
KR101865974B1 (ko) * 2009-12-07 2018-06-11 암젠 인크 β-ＫＬＯＴＨＯ, ＦＧＦ 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
KR20120098871A (ko) * 2009-12-07 2012-09-05 암젠 인크 β-ＫＬＯＴＨＯ, ＦＧＦ 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
US10570205B2 (en) 2009-12-07 2020-02-25 Amgen, Inc. Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US12116413B2 (en) 2009-12-07 2024-10-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
EP2510009A1 (en) * 2009-12-07 2012-10-17 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP3760642A1 (en) * 2009-12-07 2021-01-06 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP3670534A2 (en) * 2010-04-15 2020-06-24 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
US10093735B2 (en) 2014-01-24 2018-10-09 Ngm Biopharmaceuticals, Inc. Beta-klotho binding proteins
US11596676B2 (en) 2014-01-24 2023-03-07 Ngm Biopharmaceuticals, Inc. Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof
US10744191B2 (en) 2014-01-24 2020-08-18 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins and methods of use thereof
US11667708B2 (en) 2015-07-29 2023-06-06 Ngm Biopharmaceuticals, Inc. Anti-human beta klotho antibody or binding fragment thereof and methods of their use
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
US11802152B2 (en) 2015-08-03 2023-10-31 Novartis Ag Methods of treating FGF21-associated disorders
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
US11692046B2 (en) 2017-02-08 2023-07-04 Novartis Ag FGF21 mimetic antibodies and uses thereof

Also Published As

Publication number Publication date
JP5545504B2 (ja) 2014-07-09
US20100184665A1 (en) 2010-07-22
US8697369B2 (en) 2014-04-15
JP2009073807A (ja) 2009-04-09
JP5187837B2 (ja) 2013-04-24
JP2012230113A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
WO2008123625A1 (ja) 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2007067946A3 (en) Diagnosis and treatment of chronic lymphocytic leukemia (cll)
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2007005453A3 (en) Compositions for treating or preventing obesity and insulin resistance disorders
WO2005020892A3 (en) Pharmaceutical compositions and methods for metabolic modulation
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007024700A3 (en) Exendin for treating diabetes and reducing body weight
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
WO2007109120A3 (en) Imidazolothiazole compounds for the treatment of disease
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007128817A3 (en) Insulin derivative
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
CL2007002348A1 (es) Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
WO2011159067A3 (en) Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
WO2007120655A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2009004082A3 (en) Anticonvulsive pharmaceutical compositions
WO2009068246A3 (en) Methods of treating obesity and metabolic disorders
WO2007120688A3 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
BRPI0510697A (pt) gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete
WO2013109342A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740009

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12594210

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740009

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载